efruxifermin (AKR-001) / Akero Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
efruxifermin (AKR-001) / Akero Therap
AK-US-001-0107, NCT06161571: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Recruiting
3
700
Europe, Canada, US, RoW
Efruxifermin, Placebo
Akero Therapeutics, Inc
NASH/MASH, NAFLD/MASLD
04/26
10/26
AK-US-001-0105, NCT06215716: A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Recruiting
3
1650
Europe, Canada, US, RoW
Efruxifermin, Placebo
Akero Therapeutics, Inc
NASH With Fibrosis, MASH With Fibrosis
11/32
11/32
AK-US-001-0106, NCT06528314: A Study Evaluating Efruxifermin in Subjects with Compensated Cirrhosis Due to NASH/MASH

Recruiting
3
1150
Europe, Canada, US, RoW
Efruxifermin, Placebo
Akero Therapeutics, Inc
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
09/29
10/29
Harmony, NCT04767529: A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Active, not recruiting
2b
128
US
EFX, Placebo
Akero Therapeutics, Inc
NASH - Nonalcoholic Steatohepatitis
07/22
05/24
Symmetry, NCT05039450: A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Active, not recruiting
2b
200
US, RoW
EFX, Placebo
Akero Therapeutics, Inc
NASH - Nonalcoholic Steatohepatitis
10/23
04/24

Download Options